(Q33835047)

29 July 2017

1 reference

title

The consideration of immunotherapy in the treatment of allergic asthma (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

Creticos PS

1

1 reference

PubMed ID

10669541

29 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

The Journal of Allergy and Clinical Immunology

29 July 2017

1 reference

29 July 2017

105

1 reference

29 July 2017

2 Pt 2

1 reference

29 July 2017

S559-74

1 reference

Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Deposition of Inhaled Pollen and Pollen Extract in Human Airways

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunochemical quantitation of airborne short ragweed, Alternaria, antigen E, and Alt-I allergens: a two-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Dust mites: immunology, allergic disease, and environmental control.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Dust mite allergens and asthma—A worldwide problem

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Peptide Leukotriene Release after Antigen Challenge in Patients Sensitive to Ragweed

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Inflammatory mediators in late antigen-induced rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Generation of Antigen-Specific Suppressor Cells during Allergy Desensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

The magnitude of the spontaneous production of histamine-releasing factor (HRF) by lymphocytes in vitro correlates with the state of bronchial hyperreactivity in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

The nasal response to histamine challenge: Effect of the pollen season and immunotherapy+§

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Stimulation of phospholipid methylation, Ca2+ influx, and histamine release by bridging of IgE receptors on rat mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

SEROLOGICAL EVIDENCE OF IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY FEVER).

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Seasonal changes in IgE antibodies and their relationship to IgG antibodies during immunotherapy for ragweed hay fever

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy with allergens

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Responses to ragweed-pollen nasal challenge before and after immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

The role of ragweed pollen in autumnal asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Ragweed immunotherapy in adult asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy for cat asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Fatalities from immunotherapy (IT) and skin testing (ST)

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

ACE inhibitors and anaphylactoid reactions during venom immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy in cat-induced asthma *1Double-blind trial with evaluation of bronchial responses to cat allergen and histamine

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Control examination of the specificity of specific desensitization in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Hyposensitization in house dust allergy asthma. A double-blind controlled study with evaluation of the effect on bronchial sensitivity to house dust

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Hyposensitization with Dermatophagoides pteronyssinus antigen: trial in asthma induced by house dust.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Immunotherapy for mountain cedar pollinosis. A double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-grass pollen mixture respectively

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

A controlled trial of immunotherapy for asthma in allergic children

1 reference

https://api.crossref.org/works/10.1016%2FS0091-6749%2800%2990060-5

7 January 2021

10.1016/S0091-6749(00)90060-5

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10669541